-
-
-
-
-
-
-
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
-
-
-
-
-
-
-
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $45 Per Share, $8.7 Billion Deal
-
-
-
-
-
-
-
AbbVie (ABBV) shares dip as revenue drops 6% from last year
-
-
-
-
-
-
-
AbbVie (ABBV) Tops Q2 EPS by 4c, Raises FY Guidance
-
-
-
-
-
-
-
AbbVie (ABBV) shares slide despite revenue beat
-
-
-
-
-
-
-
Abbvie (ABBV) Humira guidance removes overhang - Truist
-
-
-
-
-
-
-
Abbvie (ABBV) PT Raised to $159 at Evercore ISI, Expects $11.38 EPS, 'we’re constructive on the stock heading into earnings'
-
976,689 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All